Acasunlimab

Phase 3

GENMAB A/S (GNMSF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

GNMSFPhase 3$21.5B

Acasunlimab Phase 3 Est. Readout

Acasunlimab• PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC191

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

View Full Landscape

Drug Information

Target Indication

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Clinical Trial

NCT06635824

Last updated: 8/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GNMSF

GENMAB A/S

Biotechnology•North America•NASDAQ

Related Pipeline

ZalutumumabPhase 3

Head and Neck Neoplasms

EpcoritamabPhase 3

DLBCL

Rina-SPhase 3

Non-small Cell Lung Cancer (NSCLC)

Investigator's Choice ChemotherapyPhase 3

Diffuse Large B-cell Lymphoma

PetosemtamabPhase 3

Left-sided Colorectal Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts